We are live on ! Find out more
CAPR icon

Capricor Therapeutics
CAPR

21 hedge funds and large institutions have $3.01M invested in Capricor Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

17% more capital invested

Capital invested by funds: $2.57M → $3.01M (+$446K)

5% more funds holding

Funds holding: 20 → 21 (+1)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.03% less ownership

Funds ownership: 0.45% → 0.42% (-0.03%)

Holders
21
Holders Change
+1
Holders Change %
+5%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$171K
2
AA
Apriem Advisors
California
+$139K
3
VKH
Virtu KCG Holdings
New York
+$74.1K
4
BlackRock
BlackRock
New York
+$53.3K
5
Northern Trust
Northern Trust
Illinois
+$47.4K

Top Sellers

1
SM
Sabby Management
Florida
-$373K
2
Brown Advisory
Brown Advisory
Maryland
-$189K
3
Goldman Sachs
Goldman Sachs
New York
-$49.3K
4
Morgan Stanley
Morgan Stanley
New York
-$41.6K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$38K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$791K -$373K -13,446 -36%
CBA
2
Coastal Bridge Advisors
Connecticut
$489K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$221K +$43.1K +1,554 +31%
Jacobs Levy Equity Management
4
Jacobs Levy Equity Management
New Jersey
$209K +$171K +6,173 New
Goldman Sachs
5
Goldman Sachs
New York
$195K -$49.3K -1,777 -24%
GPCM
6
Granite Point Capital Management
Massachusetts
$193K -$26.2K -945 -14%
AA
7
Apriem Advisors
California
$169K +$139K +5,000 New
FWM
8
Frontier Wealth Management
Missouri
$159K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$154K +$6.83K +246 +6%
VKH
10
Virtu KCG Holdings
New York
$90K +$74.1K +2,669 New
Morgan Stanley
11
Morgan Stanley
New York
$81K -$41.6K -1,500 -38%
BlackRock
12
BlackRock
New York
$65K +$53.3K +1,920 New
Northern Trust
13
Northern Trust
Illinois
$58K +$47.4K +1,709 New
Bank of New York Mellon
14
Bank of New York Mellon
New York
$51K +$41.5K +1,496 New
HIIFS
15
Harel Insurance Investments & Financial Services
Israel
$24K – – –
AIM
16
Acrospire Investment Management
Illinois
$16K +$13.1K +473 New
PA
17
Perceptive Advisors
New York
$13K – – –
CFN
18
Cordasco Financial Network
Florida
$10K – – –
Bank of America
19
Bank of America
North Carolina
$10K +$111 +4 +1%
UBS Group
20
UBS Group
Switzerland
$9K +$6.44K +232 +892%
FANJ
21
Financial Architects (New Jersey)
New Jersey
$7K – – –
Brown Advisory
22
Brown Advisory
Maryland
– -$189K -7,107 Closed
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
– -$38K -1,432 Closed

CAPR Hedge Fund Activity: Q1 2017 in Review

21 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2017, worth a combined $3.01M — up 17% from $2.57M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CAPR positions and 2 closed out — a net gain of 5 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $171K. The largest seller was Sabby Management, cutting an estimated $373K.

  • 21 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2017, up from 20 in Q4 2016.
  • Funds reported $3.01M of Capricor Therapeutics stock for Q1 2017, up 17% quarter-over-quarter.
  • 7 funds opened new Capricor Therapeutics positions in Q1 2017 and 2 closed out, a net change of +5 holders.
  • The largest Capricor Therapeutics buyer in Q1 2017 was Jacobs Levy Equity Management, an estimated $171K added.
  • The largest Capricor Therapeutics seller in Q1 2017 was Sabby Management, an estimated $373K sold.

Based on aggregated 13F filings for Q1 2017.